Good News | Hybio Pharmaceutical Completes Official NMPA Registration for Tirzepatide API
Recently, the National Medical Products Administration (NMPA) information platform published an update showing that Hybio Pharmaceutical (Wuhan) Co., Ltd. has completed the official registration for its Tirzepatide active pharmaceutical ingredient (API) (Registration No. Y20250001478; Last updated: January 8, 2026). The listing indicates that the product is a domestically manufactured API and that multiple packaging specifications have been filed.
This successful registration marks an important milestone in Hybio Pharmaceutical’s industrialization strategy in GLP-1 Receptor Agonists and multi-target metabolic therapies, reflecting formal inclusion and confirmation within China’s national regulatory framework.
As a highly representative multi-target peptide in the global metabolic disease field, Tirzepatide has significant clinical value in diabetes treatment, weight management, and interventions for metabolic syndrome. Industrializing this molecule sets exceptionally high requirements for Peptide Synthesis precision, scale-up capabilities for large-scale manufacturing, and end-to-end quality management systems.
The public listing of Hybio’s Tirzepatide API on the NMPA platform indicates that the company has systematically completed process route optimization, quality standard development, and the establishment of a scalable manufacturing system for this molecule—laying a solid foundation for subsequent formulation development, regulatory progress, and industrial partnerships. The completion of this registration is not a single isolated milestone, but rather a phased achievement reflecting Hybio’s long-term commitment to peptide therapeutics and continuous enhancement of its technology and industrial platform. It also demonstrates Hybio’s comprehensive capabilities in engineering complex peptide molecules, large-scale manufacturing, and quality system development, further strengthening the company’s industrial base in metabolic peptide therapeutics and next-generation weight-loss drugs.
With global demand for metabolic disease therapies continuing to rise, multi-target Peptide Drugs are becoming a key force driving industry advancement. Building on the successful registration of its Tirzepatide API, Hybio Pharmaceutical will continue to deepen its strategic focus on multi-target metabolic therapies, accelerate the development of high-barrier, large-scale peptide manufacturing capabilities, and actively expand domestic and international regulatory and collaboration pathways—providing strong support for strengthening the core competitiveness of China’s peptide pharmaceutical industry chain.
About Hybio Pharmaceutical
Hybio Pharmaceutical is an A-share listed national high-tech enterprise focused on the research, development, manufacturing, and commercialization of innovative medicines. With more than 20 years of expertise in peptide drugs, the company has built a comprehensive formulation pipeline covering major global peptide targets, including but not limited to innovative GLP-1R/GIPR/GCGR triple receptor agonists, Retatrutide, Tirzepatide, Semaglutide, and Liraglutide, as well as other globally significant peptide ANDA products.
Hybio Pharmaceutical has been granted nearly 500 patents worldwide and was the first company globally to obtain U.S. FDA approval for a Liraglutide ANDA daily formulation. Its products have successfully entered regulated markets in Europe and the United States.